Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
One-Step Approaches for Regenerative Medicine—Rationale, Characterization, and Outcomes for the...
share announcement

One-Step Approaches for Regenerative Medicine—Rationale, Characterization, and Outcomes for the Use of Regenerative Medicine Products

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (25 November 2022) | Viewed by 5850

Special Issue Editors

Dr. Marco Viganò

E-Mail Website
Guest Editor
Orthopedics Biotechnology Lab, a research department of IRCCS Galeazzi Orthopedic Institute in Milan, Milan, Italy
Interests: orthopedics; tendon pathologies; osteoarthritis; regenerative medicine; mesenchymal stem cells; growth factors and secretome
Dr. Antonio Marmotti

E-Mail Website
Guest Editor
Department of Orthopaedics, Traumatology University of Torino, Turin, Italy
Interests: cartilage; stem cells; knee surgery

Special Issue Information

Dear Colleagues, 

The field of regenerative medicine is rapidly expanding, involving several clinical specialties. The great number of devices available as one-step approaches represents both a wide range of solutions and a possible source of confusion. Indeed, from blood-derived products to cell/tissue concentrates, each product has specific procedures for preparation and administration, resulting in specific characteristics. The description of these features from independent laboratories followed by a peer-review process would allow for describing the content and the potential of each product, favoring the standardization of the procedures. This would promote the informed and most appropriate application of these treatments in the clinical practice. At the same time, evidence from case series, retrospective analysis or randomized clinical trials would provide real-world and experimental data about the safety and efficacy of these approaches in different clinical settings.

Dr. Marco Viganò
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • regenerative medicine
  • blood-derived products
  • cell/tissue concentrates
  • real-world and experimental data
  • safety and efficacy
  • mesenchymal stem cells
  • growth factors and secretome

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 9730 KiB  
Article
Differentiation of Adipose-Derived Stem Cells into Smooth Muscle Cells in an Internal Anal Sphincter-Targeting Anal Incontinence Rat Model
by Minsung Kim, Bo-Young Oh, Ji-Seon Lee, Dogeon Yoon, You-Rin Kim, Wook Chun, Jong Wan Kim and Il Tae Son
J. Clin. Med. 2023, 12(4), 1632; https://doi.org/10.3390/jcm12041632 - 17 Feb 2023
Viewed by 1314
Abstract
Objective: Studies on development of an anal incontinence (AI) model targeting smooth muscle cells (SMCs) of the internal anal sphincter (IAS) have not been reported. The differentiation of implanted human adipose-derived stem cells (hADScs) into SMCs in an IAS-targeting AI model has also [...] Read more.
Objective: Studies on development of an anal incontinence (AI) model targeting smooth muscle cells (SMCs) of the internal anal sphincter (IAS) have not been reported. The differentiation of implanted human adipose-derived stem cells (hADScs) into SMCs in an IAS-targeting AI model has also not been demonstrated. We aimed to develop an IAS-targeting AI animal model and to determine the differentiation of hADScs into SMCs in an established model. Materials and Methods: The IAS-targeting AI model was developed by inducing cryoinjury at the inner side of the muscular layer via posterior intersphincteric dissection in Sprague–Dawley rats. Dil-stained hADScs were implanted at the IAS injury site. Multiple markers for SMCs were used to confirm molecular changes before and after cell implantation. Analyses were performed using H&E, immunofluorescence, Masson’s trichrome staining, and quantitative RT–PCR. Results: Impaired smooth muscle layers accompanying other intact layers were identified in the cryoinjury group. Specific SMC markers, including SM22α, calponin, caldesmon, SMMHC, smoothelin, and SDF-1 were significantly decreased in the cryoinjured group compared with levels in the control group. However, CoL1A1 was increased significantly in the cryoinjured group. In the hADSc-treated group, higher levels of SMMHC, smoothelin, SM22α, and α-SMA were observed at two weeks after implantation than at one week after implantation. Cell tracking revealed that Dil-stained cells were located at the site of augmented SMCs. Conclusions: This study first demonstrated that implanted hADSc restored impaired SMCs at the injury site, showing stem cell fate corresponding to the established IAS-specific AI model. Full article
(This article belongs to the Special Issue One-Step Approaches for Regenerative Medicine—Rationale, Characterization, and Outcomes for the Use of Regenerative Medicine Products)
►▼ Show Figures

Figure 1

10 pages, 4541 KiB  
Article
Autologous Microfragmented Adipose Tissue for the Treatment of Knee Osteoarthritis: Real-World Data at Two Years Follow-Up
by Daniele Screpis, Simone Natali, Luca Farinelli, Gianluca Piovan, Venanzio Iacono, Laura de Girolamo, Marco Viganò and Claudio Zorzi
J. Clin. Med. 2022, 11(5), 1268; https://doi.org/10.3390/jcm11051268 - 25 Feb 2022
Cited by 14 | Viewed by 2305
Abstract
The purpose of the present study was to assess, prospectively, the safety, clinical effectiveness, and feasibility of a single intra-articular injection of microfragmented adipose tissue in different stages of knee osteoarthritis (OA). The study included patients (aged 18–70 years), affected by OA (Kellgren–Lawrence I-IV). [...] Read more.
The purpose of the present study was to assess, prospectively, the safety, clinical effectiveness, and feasibility of a single intra-articular injection of microfragmented adipose tissue in different stages of knee osteoarthritis (OA). The study included patients (aged 18–70 years), affected by OA (Kellgren–Lawrence I-IV). Unselected patients were evaluated before and prospectively after 6, 12, and 24 months from the injection. Visual analog scale (VAS) and knee injury and osteoarthritis outcome score (KOOS) were used for clinical evaluations. A total of 202 patients were eligible. The mean follow-up time in the cohort of patients was 24.5 ± 9.6 months. Total KOOS significantly improved from pre-operative baseline levels to 6-month follow-up (p < 0.001), and again between 6- and 12-month follow-ups (p < 0.001). The VAS showed a prompt reduction at 6 months (p < 0.001 vs. baseline), but then it increased again at 12 months compared to the 6-month assessment (p < 0.001), even though it remained lower than baseline (p < 0.001). At 24 months, patients with KL-IV demonstrated a lower improvement compared to baseline; patients that had undergone previous corticosteroid injections had a greater risk to further injection treatment. The collected clinical results suggest that MFAT may represent a safe and effective treatment for OA symptoms, offering a low-demanding and minimally invasive treatment. Full article
(This article belongs to the Special Issue One-Step Approaches for Regenerative Medicine—Rationale, Characterization, and Outcomes for the Use of Regenerative Medicine Products)
►▼ Show Figures

Figure 1

13 pages, 272 KiB  
Article
Ten-Year Stability of Clinical Attachment after Regenerative Treatment of Infrabony Defects and Controls
by Hari Petsos, Ilona Koronna, Tatjana Ramich, Katrin Nickles, Bettina Dannewitz, Beate Schacher and Peter Eickholz
J. Clin. Med. 2022, 11(3), 543; https://doi.org/10.3390/jcm11030543 - 21 Jan 2022
Viewed by 1395
Abstract
Background: A similar long-term stable clinical attachment level (CAL) of infrabony defects (IBDs) after regenerative treatment compared to control teeth would indicate a high level of stability resulting from the regenerative approach. Methods: Patients with a regeneratively treated IBD were screened 120 ± [...] Read more.
Background: A similar long-term stable clinical attachment level (CAL) of infrabony defects (IBDs) after regenerative treatment compared to control teeth would indicate a high level of stability resulting from the regenerative approach. Methods: Patients with a regeneratively treated IBD were screened 120 ± 12 months postoperatively for eligibility for study participation, and were included if complete baseline and 12-month examinations (plaque (PlI), periodontal probing depth (PPD), CAL) were available and a respective control tooth could be identified. Re-examination included clinical examination (PPD, CAL, PlI/GI, bleeding on probing, plaque control record, gingival bleeding index). Results: A total of 27 patients (16 females; age (median; lower/upper quartile): 57.0; 44.0/60.0 years; 6 smokers) contributed 27 IBDs (test), for each of which a control tooth was identified. Five test teeth (18.5%) were lost between 12 and 120 months. The remaining 22 test teeth revealed a significant CAL gain after 1 (2.5 mm; 1.0/4.0 mm, p < 0.0001) and 10 (2.5 mm; 0.5/3.5 mm, p < 0.0001) years, whereas control teeth were stable (1 year: 0.0 mm; 0.0/1.0 mm, p = 0.396; 10 years: 0.0 mm; −1.0/1.5 mm, p = 0.215). The study did not detect any significant CAL change between 1 and 10 years for test (−0.5 mm; −1.0/0.5 mm, p = 0.414) and control teeth (0.0 mm; −1.0/1.0 mm, p = 0.739). In 15 patients, test and control teeth revealed stable CAL values between 12 and 120 months. Conclusion: Regenerative treatment of IBDs exhibited stability comparable to non-surgically treated, periodontally reduced sites over a 10-year period. Full article
(This article belongs to the Special Issue One-Step Approaches for Regenerative Medicine—Rationale, Characterization, and Outcomes for the Use of Regenerative Medicine Products)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop